Control of vascular morphogenesis and homeostasis through the angiopoietin–Tie system

By H. Augustin, G. Koh, Gavin Thurston, K. Alitalo. Nature reviews. Molecular cell biology, 2009

1,423 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/29ac23113e7563e159ac06ca81407033bb9d2b75

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. Peter Carmeliet
2. Rakesh K. Jain
3. K. Alitalo

In Molecular Biology

1. Rakesh K. Jain
2. N. Ferrara
3. Peter Carmeliet
4. K. Alitalo
5. A. Adamis
6. M. Potente
7. R. Apte
8. Daniel Chen

Citations in the corpus

• Molecular control of endothelial cell behaviour during blood vessel morphogenesis (2011, background): “For example, disruption of angiopoietin 1 (ANG1) signalling via the TIE2 (also known as TEK) receptor Tyr kinase by the antagonist ANG2 is thought to destabilize vessels and have key roles during early angiogenic vascular remodelling (this is covered in another revie”
• Targeting the tumour vasculature: insights from physiological angiogenesis (2010, background): “The Ang–TIE2 system in tumour angiogenesis functions similarly to physiological angiogenesi”
• Regorafenib (BAY 73‐4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity (2011, background): “Constitutive Ang1 expression is found in pericytes, smooth muscle cells, fibroblasts and some tumor cells, while Ang2 expression is tightly controlled and almost exclusively expressed by endothelial cells.(11) Expression studies have shown that Ang2 and/or VEGF are upregulated in a variety of human ”
• Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases (2011, background): “Another example of a molecular pathway that regulates vessel normalization is the ANG–TIE (tunica interna endothelial cell kinase) receptor axis, which controls vessel maturation in a contextual fashio”
• VEGF in Signaling and Disease: Beyond Discovery and Development (2019, background): “Considerable research is being devoted to the hypothesis that combining VEGF inhibitors with activators of the tyrosine kinase Tie2 may achieve greater efficacy than anti-VEGF monotherapy owing to the stabilizing role of Tie2 on the vasculature, with potential reduction in vascular leakage (Augustin”
• Basic and therapeutic aspects of angiogenesis. (2011, positive): “VEGFR1+ hematopoietic precursors or TIE2-expressing monocytes (TEMs) are located close to growing tumor vessels and release angiogenic molecules (De Palma and Naldini, 2009).”
• Lymphangiogenesis: Molecular mechanisms and future promise. (2010, background): “The angiopoietin (Ang) growth factors bind to the receptor tyrosine kinase Tie2 that is expressed almost exclusively in endothelial cells and regulate interactions between endothelial cells and mural cells (Augustin et al., 2009).”
• Tumor angiogenesis and vascular normalization: alternative therapeutic targets (2017, background): “Ang1-induced Tie2 phosphorylation leads to AKT activation, which promotes survival pathways in ECs, suppresses apoptotic pathways and deactivates the forkhead transcription factor (FOXO1) [28, 29].”
• NORMALIZATION OF THE VASCULATURE FOR TREATMENT OF CANCER AND OTHER DISEASES (2011, neutral): “The mechanisms for PVC detachment in tumors are multiple, but include a VEGF-mediated disruption of PDGFRactivity (110), and overexpression of Ang-2, the endogenous “antagonist” of Ang-1 (8).”
• Ten years of anti-vascular endothelial growth factor therapy (2016, background): “…system involved in multiple physiological and pathological processes, including blood vessel sprouting and maintenance, lymphangiogenesis, recruitment of myeloid cells and metastasis 153,154 , as preclinical studies have shown marked additivity with VEGFA inhibitors in various tumour models 155 .”
• The lymphatic vasculature in disease (2011, background): “In addition, the angiopoietins and their Tie receptors have been implicated in lymphangiogenesi”
• Targeting the ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells. (2011, background): “, 2004); the role of ANG2 in tumor angiogenesis and growth—and its therapeutic significance as a molecular target—remains controversial and poorly defined (Augustin et al., 2009; Saharinen et al., 2010).”
• Molecular mechanisms and clinical applications of angiogenesis (2011, background): “Because no ligand for TIE-1 has been identified, this orphan receptor may act as a negative regulator of TIE-2, but its precise role remains elusiv”